AUSTIN, Texas, Aug. 26 /PRNewswire-FirstCall/ — Luminex
Corporation (Nasdaq:
LMNX), the worldwide leader in multiplexed solutions, today
announced the full commercial launch of its xTAG® Cystic
Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously
screen a single blood sample for up to 60 cystic fibrosis-causing
genetic mutations in a matter of hours.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)
The test is the most comprehensive and flexible FDA-cleared
cystic fibrosis (CF) test available, featuring an unsurpassed level
of gene mutation coverage. It will be used to screen
potential parents to determine if they are carriers of CF-causing
gene mutations, and as an aid in newborn screening and in
confirmatory diagnostic testing in newborns and children. The
test recently received 510(k) clearance from the U.S. Food and Drug
Administration (FDA).
“The launch of our new xTAG Cystic Fibrosis 60 Kit v2 is a great
achievement in cystic fibrosis testing,” said Patrick J. Balthrop,
president and chief executive officer of Luminex. “This cleared
test has the most comprehensive genetic mutation coverage available
today, featuring mutations found among Caucasians as well as those
that are more commonly found in other ethnic populations. It
will give doctors the ability to screen children and potential
parents of many ethnicities for CF.”
Cystic fibrosis is a common genetic disorder that causes the
body to produce thick mucus that can clog the lungs and affect the
digestive system. Approximately 30,000 Americans have cystic
fibrosis. Although CF is most common in those of Caucasian
desce
‘/>”/>
